Contact us
Qiagen is one of our top pick in the healthcare sector. Our favourable opinion is based on several factors: healthcare systems under pressure to make greater use of diagnostics to reduce the waste generated by ineffectual treatments (currently USD 350 billion); a dominant position on the competition scene; robust pricing power and important news flow in 2010.
Qiagen published its Q2 2010 results last night after the markets had closed. Performance proved somewhat disappointing, although it did fall within the range previously announced by the management. In general, pressures exerted on margins are not linked to a deterioration of the price environment. Despite all these factors, we will monitor the next quarters closely. PLUS code maintained. Negative reaction expected.
Qiagen is our new PLUS recommendation in the healthcare sector. Our favourable opinion is based on several factors: healthcare systems under pressure to make greater use of diagnostics to reduce the waste generated by inefficient treatments (currently USD 350 billion); a dominant position on the competition scene; robust pricing power and important news flow in 2010.
version française